Search - tctmd.com

Displaying 41 - 60 of 86

Sort: Relevancy | Date

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

Presentation ESC 2019

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Presenter: Deepak Bhatt

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo

Presentation ESC 2018

ASCEND A Randomized Trial of Omega-3 Fatty Acids (fish oil) vs Placebo

Presenter: Jane Armitage

August 27, 2018

Presentation ESC 2018

ASCEND Randomized placebo-controlled trial of aspirin

Presenter: Jane Armitage

August 27, 2018

News Conference News ESC 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Todd Neale

August 27, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

Todd Neale

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

Presentation ESC 2017

PCI vs CABG in Patients with Type 1 Diabetes and Multivessel Disease

Presenter: Martin J. Holzmann

August 28, 2017

Advertisement

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

TCTMD’s Top 10 Most Popular Stories for September 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

TCTMD’s Top 10 Most Popular Stories for September 2018

TCTMD’s Top 10 Most Popular Stories for August 2018

ASCEND A Randomized Trial of Omega-3 Fatty Acids (fish oil) vs Placebo

ASCEND Randomized placebo-controlled trial of aspirin

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

PCI vs CABG in Patients with Type 1 Diabetes and Multivessel Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content